Popular on eTradeWire
- Flush Gallery Presents Moral Injury, a group show, at Hercules Art Studio - 142
- Concrete Engine Unveils First Product Demo at Rally Innovation 2024 - 108
- League of Women Voters PBC to Present Nonpartisan ELECTION EXPO 2024 on Sept 30 - 108
- Parsley Unveils New Integrations and Enhanced Features to Streamline Recruiting - 107
- Florida Native Plant Society PBC Opposes Destruction of Lands at Jonathan Dickinson State Park - 107
- Get Ready for Fun: A New Sports Center is Coming Soon To Colony Ridge! - 105
- Newly Appointed Holman Pastors Continue Lawson's Legacy - 104
- 5 Questions to Ask Before Hiring a Roofing Contractor in Memphis, Tennessee - 104
- Big News for Colony Ridge Community: A New High School Is Coming Soon! - 103
- John Vuitton CEO of John Vuitton Entertainment, Earns MRAA Palladium Certification for "Tank Moves"
Similar on eTradeWire
- GoGo Roofing Introduces Expanded Services: Now Offering Roofing Solutions in New Georgia Communities
- "The 83 Theses" Presents a Revolutionary Exploration of the Universe and Consciousness
- September is "International Update Your Resume Month"
- AI-based Tissue Staining to Detect Amyloid Deposits Without Chemical Stains or Microscopy
- What to do if you receive a litigation hold notice
- Colony Ridge Welcomes A Second DG Market!
- Everglades Family Dental: Comprehensive Family Dentistry in Pembroke Pines, FL
- AllTech Air Conditioning Earns Spot on 2024 Inc. Magazine's 5000 List
- PitchSlap Prepares to Launch, Promises to Clean Up Your Inbox from Sales Email Clutter
- Portland's Ron Turker M.D. Brings a Humorous and Revealing Look at Big Medicine to Audiobook This Fall
OncoBeta announces the expansion of Rhenium-SCT for non-melanoma skin cancer patients in Italy
eTradeWire News/10777441
BOZEN, Italy - eTradeWire -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, has announced the expansion of Rhenium-SCT® (Skin Cancer Therapy) treatment services in Italy with the Bolzano Hospital the latest to come on board. This marks a significant advancement in the availability of non-melanoma skin cancer (NMSC) treatment options within the country.
Rhenium skin cancer therapy is an advanced radionuclide therapy that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly over the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Dr. Mohsen Farsad at Bolzano Hospital has been impressed with the Rhenium-SCT device, noting, "I have witnessed impressive outcomes with several patients treated here in Italy already, and am pleased with the design of the device technology."
"Rhenium skin cancer therapy fulfills many patients' desires for a non-surgical alternative for the treatment of NMSCs especially in relation to difficult localisations. I am pleased to continue treating suitable patients with Rhenium-SCT", adds Dr. Farsad.
Shannon D. Brown III, CCO at OncoBeta, says, "While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption."
According to GLOBOCAN estimates, the number of new NMSC cases in Italy is projected to rise from 29,000 to 41,700 between 2022 and 2045.5 Epidemiological data for Europe shows an annual incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per 100,000 women. Basal cell carcinoma (BCC) accounts for approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100 cases per 100,000 inhabitants.6
Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasised, "Rhenium-SCT enables targeted, non-invasive treatment of NMSCs while preserving adjacent healthy tissue. This patient-friendly approach underscores our commitment to enhancing treatment options for those affected by NMSCs."
More on eTradeWire News
Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,7 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,7 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,7,8
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
More on eTradeWire News
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
About DSD Pharma
DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.
Find out more about DSD Pharma at www.dsd-pharma.com
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.9
References
Rhenium skin cancer therapy is an advanced radionuclide therapy that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly over the NMSC lesion, targeting cancer cells without the need for surgery.1,4
Dr. Mohsen Farsad at Bolzano Hospital has been impressed with the Rhenium-SCT device, noting, "I have witnessed impressive outcomes with several patients treated here in Italy already, and am pleased with the design of the device technology."
"Rhenium skin cancer therapy fulfills many patients' desires for a non-surgical alternative for the treatment of NMSCs especially in relation to difficult localisations. I am pleased to continue treating suitable patients with Rhenium-SCT", adds Dr. Farsad.
Shannon D. Brown III, CCO at OncoBeta, says, "While surgical intervention remains the standard-of-care for NMSC treatment, it often leads to suboptimal outcomes. Rhenium-SCT offers a non-surgical alternative with a simple application directly to the area needed to treat, and allows patients to resume their daily activities with minimal disruption."
According to GLOBOCAN estimates, the number of new NMSC cases in Italy is projected to rise from 29,000 to 41,700 between 2022 and 2045.5 Epidemiological data for Europe shows an annual incidence rate of NMSCs at 129.3 cases per 100,000 men and 90.8 per 100,000 women. Basal cell carcinoma (BCC) accounts for approximately 15% of all diagnosed cancers in Italy, with an annual incidence of around 100 cases per 100,000 inhabitants.6
Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasised, "Rhenium-SCT enables targeted, non-invasive treatment of NMSCs while preserving adjacent healthy tissue. This patient-friendly approach underscores our commitment to enhancing treatment options for those affected by NMSCs."
More on eTradeWire News
- "The 83 Theses" Presents a Revolutionary Exploration of the Universe and Consciousness
- September is "International Update Your Resume Month"
- 16th Annual Treasure Coast Marine Flea Market and Seafood Festival Set to Sail into Vero Beach
- "The 83 Theses" Unveils a New Perspective on Existence and White Power
- Mediaset Acquires Another 5% of The Masters of Money Family of Companies For $85,000,000
Rhenium-SCT is currently available in Germany, Austria, Switzerland, Italy, Spain, United Kingdom, South Africa and Australia. Rhenium-SCT will be provided to patients at Bolzano Hospital by OncoBeta's distribution partner, DSD Pharma.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4
The Rhenium-SCT is a painless,*1,2 single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,7 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,7 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,7,8
About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
More on eTradeWire News
- IBC 2024: MC-IF Member Ericsson Showcases VVC Integration for Cloud Gaming and Mobile Device and Service Providers
- IBC 2024: MC-IF Member Nokia Demonstrates Real-Time AI Enhanced VVC
- IBC 2024: MC-IF Member, Qualcomm, Unveils Revolutionary VVC Demo on Snapdragon X Elite
- RideBoom Seeks Electric Vehicle Manufacturers to Join Forces in Redefining Last-Mile Transportation
- Fernanda Rocha Launches New YouTube Fitness Channel, Empowering Busy Moms to Prioritize Their Health
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
About DSD Pharma
DSD Pharma is a distributor for diagnostics, theranostics and radiopharmaceutical/medical devices in the field of nuclear medicine and radiopharmaceuticals. DSD Pharma offers a product portfolio developed together at the forefront of research to its customers. This ensures the safety of latest technologies for the HCP and the best available diagnosis/theranosis/therapy for the patient.
Find out more about DSD Pharma at www.dsd-pharma.com
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions treated.3
‡A treatment is considered non-invasive when no cut or break in the skin is created.9
References
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
- Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
- Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Sordi E, et al. Epidemiologia. 2024;5:1–10.
- Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
- Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).
Source: OncoBeta GmbH
0 Comments
Latest on eTradeWire News
- Utah County Auto Glass Store Under New Ownership
- Vantiva Wins CSI Award for "Best Sustainability Project or Initiative" for Eco-Friendly V7c Android TV Set Top Box
- Detroit's Underground Music Scene Comes Alive: "Offstage" TV Show Now Streaming on YouTube Music
- Skool O' Foolz Drops Rapperz Delite on Gum Drop Hip Hop You Tube Channel From TVS Records
- Sheltering Arms Announces the "Embrace Early & Create the Future" Street Party
- PitchSlap Prepares to Launch, Promises to Clean Up Your Inbox from Sales Email Clutter
- Softdocs Supports Cities Through GMA Participation
- Roofer Urges Homeowners to Install New Roofs Before Winter for Optimal Protection and Energy Savings
- Portland's Ron Turker M.D. Brings a Humorous and Revealing Look at Big Medicine to Audiobook This Fall
- Ketamine Lead Gen Makes Major Moves in Mental Health and Wellness Market Expansion
- Dance and Sing Along to ABBA's Greatest Hits at the Weinberg Center
- Quality Care Group Thrilled to be Finalists in Three Categories at the Leaders in Care Awards 2024
- "A Life Worth Living" Traces a Cardiologist's Rewarding Career Journey
- Inframark Announces New Chief Financial Officer
- Empowering Communities: Ocean Partnership for Children's Commitment to Suicide Prevention Month
- Escajeda Holdings Highlighted in Forbes, Fortune, and Entrepreneur Magazines
- Best Rated Removals Swindon Expands Services Across the Entire UK
- Cellhire Wins Connectivity Gold at the Paris 2024 Games
- VVC Ready for Deployment: An Exclusive Conversation with Lukasz Litwic at IBC 2024
- Jamie Purser Appointed as New Principal/CEO to Lead Newham College London